stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) Return on equity
Adaptive Biotechnologies Corporation's return on equity over the twelve months to 30 September 2026 was −36.3%, down 8.5 percentage points from fiscal 2025 (−27.8%). Over the past ten years it has ranged from −62.5% (fiscal 2024) to 19.2% (fiscal 2018); the current reading is higher than 67% of that period. That is below the Diagnostics & Research industry median of 0.00% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −27.8% | 34.61 |
| FY2024 | −62.5% | (4.12) |
| FY2023 | −58.3% | (20.85) |
| FY2022 | −37.5% | (6.71) |
| FY2021 | −30.8% | (8.52) |
| FY2020 | −22.3% | 22.21 |
| FY2019 | −44.5% | (63.66) |
| FY2018 | 19.2% | 1.52 |
| FY2017 | 17.7% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CDNA CareDx, Inc. compare | 33.0% |
| SHC Sotera Health Company compare | 27.0% |
| VCYT Veracyte, Inc. compare | 9.43% |
| BLLN BillionToOne, Inc. compare | 0.00% |
| RDNT RadNet, Inc. compare | −1.64% |
| NEO NeoGenomics, Inc. compare | −3.94% |
| GRAL GRAIL, Inc. compare | −17.3% |
| ADPT Adaptive Biotechnologies Corporation | −36.3% |
| WGS GeneDx Holdings Corp. compare | −40.8% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ADPT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement